ArticleOncology letters2016
Tumor-penetration and antitumor efficacy of cetuximab are enhanced by co-administered iRGD in a murine model of human NSCLC.
Article in Oncology letters, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 23 citations in OpenAlex.
- Co-administered internalizing RGD peptide boosts anti-PD-L1 therapy in hepatocellular carcinoma.JHEP reports : innovation in hepatology · 2026Article
- Population Pharmacokinetic Modeling of Certepetide in Human Subjects With Metastatic Pancreatic Ductal Adenocarcinoma.Clinical pharmacology in drug development · 2025Article
- Tumour-specific activation of a tumour-blood transport improves the diagnostic accuracy of blood tumour markers in mice.EBioMedicine · 2024Article
- Significance of chitinase-3-like protein 1 in the pathogenesis of inflammatory diseases and cancer.Experimental & molecular medicine · 2024Review
- ROS-responsive dimeric prodrug-based nanomedicine targeted therapy for gastric cancer.Drug delivery · 2021Article
- Chitosan oligosaccharide modified liposomes enhance lung cancer delivery of paclitaxel.Acta pharmacologica Sinica · 2021Article
- Peptide-Based Strategies for Targeted Tumor Treatment and Imaging.Pharmaceutics · 2021Review
- Review
- Recombinant cell-permeable HOXA9 protein inhibits NSCLC cell migration and invasion.Cellular oncology (Dordrecht, Netherlands) · 2019Article
- Synthesis and evaluation ofChinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2019Article
- iRGD: A Promising Peptide for Cancer Imaging and a Potential Therapeutic Agent for Various Cancers.Journal of oncology · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer is the leading cause of cancer-associated mortality, worldwide. For this reason, novel therapies are required for the treatment of this devastating disease. Cetuximab is a monoclonal antibody against epidermal growth factor receptor (EGFR), which is overexpressed in a variety of solid tumors, including non-small cell lung cancer (NSCLC). The therapeutic efficacy of cetuximab for NSCLC is limited to use as a monotherapy or in combination with chemotherapy. The objective of the present study was to develop a novel strategy to enhance the therapeutic efficacy of cetuximab for NSCLC by a co-administration with the tumor-penetrating internalizing RGD peptide (iRGD). Human NSCLC subcutaneous xenograft models established with the A549 cell line in nude mice were treated with 30 mg/kg cetuximab, 4 mg/kg iRGD, cetuximab plus iRGD or phosphate-buffered saline. The tumor-penetration,
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.